Shenzhen Weiguang Biological Products Co., Ltd. (SZSE: 002880)
Health Care · Biotechnology · CN
CN¥21.12
+2.67% today · -28.2% 1Y
Shenzhen Weiguang Biological Products Co., Ltd. (SZSE: 002880) operates in the Biotechnology industry within the Health Care sector. The company is valued at $712.55M and employs 901 people.
Over the last twelve months the share price has lost 28.2%, trading between 18.57 and 33.79.
Tweenvest scores Shenzhen Weiguang Biological Products Co., Ltd. across four factors: quality 78/100, value 69/100, growth 62/100, dividend 47/100. Its strongest factor is quality.
002880 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $712.55M
- Revenue (TTM)
- $176.31M
- P/E
- 26.17
- EPS
- 0.81
- Dividend yield
- 0.95%
- Beta (5Y)
- 0.27
- 52-week high
- CN¥33.79
- 52-week low
- CN¥18.57
- Avg volume (3M)
- —
- Shares outstanding
- 226.80M
- Employees
- 901
- Next earnings
- —
About Shenzhen Weiguang Biological Products Co., Ltd.
Shenzhen Weiguang Biological Products Co., Ltd. is a Chinese enterprise primarily dedicated to the entire lifecycle of blood products, encompassing their research, development, manufacturing, and distribution within the domestic market. Its comprehensive portfolio features a range of crucial blood-derived therapies, including human albumin, various intravenous immunoglobulin preparations (such as pH4 and its freeze-dried counterpart), general human immunoglobulin, and specific immunoglobulins targeting conditions like hepatitis B, rabies, and tetanus. Additionally, it provides histamine human immunoglobulin and human fibrinogen. These offerings collectively represent nine distinct product types, available in twenty-one different specifications. Established in 1985, the firm maintains its headquarters in Shenzhen, China.
- ISIN
- CNE100002Q58
- Founded
- 1985
- Listed since
- Jun 16, 2017
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.31 | +0.51% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.00 | -1.43% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.